These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11450766)

  • 1. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation.
    Harding S
    Eye (Lond); 2001 Jun; 15(Pt 3):407-12. PubMed ID: 11450766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on verteporfin in subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs Aging; 2004; 21(3):203-9. PubMed ID: 14979737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Pieramici DJ; Bressler SB; Koester JM; Bressler NM
    Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.
    Fenton C; Perry CM
    Drugs Aging; 2006; 23(5):421-45. PubMed ID: 16823995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.
    Barnes RM; Gee L; Taylor S; Briggs MC; Harding SP
    Eye (Lond); 2004 Aug; 18(8):809-13. PubMed ID: 14963483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy with verteporfin in Belgian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Mori R; Kelkar A; De Laey JJ
    Bull Soc Belge Ophtalmol; 2006; (299):57-64. PubMed ID: 16681088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.
    Parodi MB; Da Pozzo S; Ravalico G
    Br J Ophthalmol; 2003 Feb; 87(2):177-83. PubMed ID: 12543747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
    Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
    Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.
    Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM;
    Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration.
    Frennesson CI; Nilsson SE
    Acta Ophthalmol Scand; 2004 Dec; 82(6):645-50. PubMed ID: 15606458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.